The Raltegravir and Ribavirin Pharmacokinetics (PK) Study
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at levels of both a new anti-HIV drug called raltegravir
and an existing anti-hepatitis C drug called ribavirin to see if they affect the blood levels
of each other when given separately and together. This is a phase I, open-label, prospective,
three phase, pharmacokinetic study.